SPRC SciSparc Ltd
Price Chart
Executive Summary
SciSparc Ltd. (SPRC) announced that its majority-owned subsidiary, NeuroThera Labs, is acquiring 54.01% of quantum technology firm CliniQuantum Ltd. in a stock-and-earnout deal valued at approximately $9.46 million, plus potential earn-outs of up to $2.5 million. The transaction reflects a strategic expansion into quantum computing for clinical trial optimization, though it is being funded entirely through equity issuance by a subsidiary, raising dilution concerns.
Key Financial Metrics
Actionable Insight
Monitor for dilution impact on SPRC shareholders via NeuroThera's share issuance; assess whether CliniQ’s quantum platform can deliver tangible R&D acceleration for SciSparc’s CNS drug programs. Watch for patent filings and fundraising activity that could trigger earn-outs.
Key Facts
- NeuroThera Labs (75%-owned by SciSparc) is acquiring 54.01% of CliniQuantum Ltd. via a share purchase agreement.
- Consideration is 56,600,000 NeuroThera shares, valued at ~$9,459,954 based on 20-day VWAP on TSXV.
- Potential earn-out payments of up to $2.5 million: $1.5M tied to patent filings, $1M to NeuroThera fundraising proceeds.
- Closing expected by March 31, 2026, subject to Israeli tax ruling and closing conditions.
- CliniQ holds quantum simulation patents from Tel Aviv University and aims to use quantum computing to improve clinical trial design.
Financial Impact
$9.46 million initial value with up to $2.5 million in contingent payments
Risk Factors
- High dilution risk: 56.6M shares issued by NeuroThera may significantly dilute SciSparc's indirect stake.
- CliniQ is pre-revenue with unproven quantum technology; commercial viability is uncertain.
- Earn-out structure benefits sellers but adds contingent liability and potential future dilution if paid in stock.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252980 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $8.55 (−25.91%) |
|
Jun 4, 2026
10d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $8.55 (−25.91%) |
|
May 29, 2026
16d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $8.55 (−12.84%) |
|
May 28, 2026
17d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $8.55 (−18.96%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $8.55 (+97.92%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $8.55 (+80.76%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $8.55 (+112.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access